Literature DB >> 12537774

Gonadotrophin-releasing hormone (GnRH) and GnRH agonists: mechanisms of action.

O Ortmann1, J M Weiss, K Diedrich.   

Abstract

The hypothalamic decapeptide gonadotrophin-releasing hormone (GnRH) binds to specific receptors on pituitary gonadotrophs. These receptors belong to the family of G protein-coupled receptors. Their activation leads to phosphoinositide breakdown with generation of inositol 1,4,5-trisphosphate (Ins(1,4,5)P3) and diacylglycerol. These second messengers initiate Ca2+ release from intracellular stores and activation of protein kinase C, both of which are important for gonadotrophin secretion and synthesis. Prolonged activation of GnRH receptors by GnRH leads to desensitization and consequently to suppressed gonadotrophin secretion. This is the primary mechanism of action of agonistic GnRH analogues. By contrast, GnRH antagonists compete with GnRH for receptors on gonadotroph cell membranes, inhibit GnRH-induced signal transduction and consequently gonadotrophin secretion. These compounds are free of agonistic actions, which might be beneficial in certain clinical applications.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12537774     DOI: 10.1016/s1472-6483(11)60210-1

Source DB:  PubMed          Journal:  Reprod Biomed Online        ISSN: 1472-6483            Impact factor:   3.828


  13 in total

Review 1.  Triptorelin: A Review of its Use as an Adjuvant Anticancer Therapy in Early Breast Cancer.

Authors:  James E Frampton
Journal:  Drugs       Date:  2017-12       Impact factor: 9.546

2.  Regulation of GnRH I receptor gene expression by the GnRH agonist triptorelin, estradiol, and progesterone in the gonadotroph-derived cell line alphaT3-1.

Authors:  J M Weiss; S Polack; O Treeck; K Diedrich; O Ortmann
Journal:  Endocrine       Date:  2006-08       Impact factor: 3.633

Review 3.  Bone health in transgender people: a narrative review.

Authors:  Giulia Giacomelli; Maria Cristina Meriggiola
Journal:  Ther Adv Endocrinol Metab       Date:  2022-05-27       Impact factor: 4.435

Review 4.  Epigenomic and enhancer dysregulation in uterine leiomyomas.

Authors:  Oliwia W Mlodawska; Priyanka Saini; J Brandon Parker; Jian-Jun Wei; Serdar E Bulun; Melissa A Simon; Debabrata Chakravarti
Journal:  Hum Reprod Update       Date:  2022-06-30       Impact factor: 17.179

5.  Fertility preservation in reproductive-age women facing gonadotoxic treatments.

Authors:  J Roberts; R Ronn; N Tallon; H Holzer
Journal:  Curr Oncol       Date:  2015-08       Impact factor: 3.677

6.  Phase I trial of TAK-385 in hormone treatment-naïve Japanese patients with nonmetastatic prostate cancer.

Authors:  Hiroyoshi Suzuki; Hiroji Uemura; Atsushi Mizokami; Narihiko Hayashi; Yasuhide Miyoshi; Satoshi Nagamori; Yutaka Enomoto; Hideyuki Akaza; Takayuki Asato; Tadayuki Kitagawa; Kazuhiro Suzuki
Journal:  Cancer Med       Date:  2019-08-19       Impact factor: 4.711

7.  Population pharmacokinetics of pevonedistat alone or in combination with standard of care in patients with solid tumours or haematological malignancies.

Authors:  Hélène M Faessel; Diane R Mould; Xiaofei Zhou; Douglas V Faller; Farhad Sedarati; Karthik Venkatakrishnan
Journal:  Br J Clin Pharmacol       Date:  2019-09-04       Impact factor: 4.335

8.  The role of gonadotropin-releasing hormone agonists in female fertility preservation.

Authors:  Jae Hoon Lee; Young Sik Choi
Journal:  Clin Exp Reprod Med       Date:  2021-02-18

9.  Screening and Validation of p38 MAPK Involved in Ovarian Development of Brachymystax lenok.

Authors:  Tianqing Huang; Wei Gu; Enhui Liu; Lanlan Zhang; Fulin Dong; Xianchen He; Wenlong Jiao; Chunyu Li; Bingqian Wang; Gefeng Xu
Journal:  Front Vet Sci       Date:  2022-02-16

Review 10.  GnRH Analogues as a Co-Treatment to Therapy in Women of Reproductive Age with Cancer and Fertility Preservation.

Authors:  Georgios Valsamakis; Konstantinos Valtetsiotis; Evangelia Charmandari; Irene Lambrinoudaki; Nikolaos F Vlahos
Journal:  Int J Mol Sci       Date:  2022-02-18       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.